Abstract: Disclosed are a negative electrode plate and a battery. A first negative active material layer is disposed at a bottom layer, and includes a first binder resistant to electrolyte swelling, has a better chemical corrosion resistance, and is not easy to age, so as to ensure long-term bonding, and reduce battery cell expansio. The negative electrode plate can maintain good mechanical strength and elongation at immersion of the electrolyte, so as to ensure that it is not separatedr. A second binder in a second negative active material layer away from the negative current collector uses a high swelling material, the high-swelling binder is in good affinity with the electrolyte, and the electrolyte infiltration speed is good, which facilitates lithium ion conduction. Furthermore, the high-swelling binder is bound to the separator well in a hot pressing process, so as to improve an interface bonding effect.

Abstract: Disclosed are a binder and a lithium-ion battery including the binder. The binder includes at least one polymer, and the polymer has a structure shown in Formula 1. The binder utilizes a composite structure in which a main chain is polyethylene glycol and both ends of a polymer chain include catechol, which respectively provide the binder with high ionic conductivity and high adhesion. A negative electrode plate including the binder features relatively has high ionic conductivity and peel strength. In addition, the binder in the present disclosure is used in a lithium-ion battery, and the lithium-ion battery has a higher cycle capacity retention rate, a lower cycle expansion rate, and higher rate performance than a lithium-ion battery using a conventional polymer binder.

Abstract: Disclosed is a lithium-ion battery, where ethylene sulfate, fluoroethylene carbonate, and a carboxylate ester organic solvent are introduced into a non-aqueous electrolyte solution, and a relationship between a negative electrode binder content X in a negative electrode plate and a DTD content A, an FEC content B, and a carboxylate ester organic solvent content Yin the non-aqueous electrolyte solution is further adjusted to meet: 10?A+B?21, 0.02?X/(A+B+Y)?0.2, and 0.02?X/Y?0.25, and a conductivity of an electrolyte solution at a low temperature and a migration rate of lithium ions may be improved, so that a negative surface may form a stable and low-impedance SEI interface, thereby improving low-temperature charging performance and high-rate discharging performance of a battery. Moreover, a cycling expansion rate of the lithium-ion battery may be reduced.

Abstract: Disclosed is a lithium-ion battery. The lithium-ion battery comprises a positive electrode, a negative electrode, a separator, and a non-aqueous electrolyte solution. The non-aqueous electrolyte solution at least comprises FEC and PP; the negative electrode comprises a binder; and the binder is a polymer having a side chain containing hydroxyl, and is a graft polymer that one or more of acrylic acid, acrylonitrile, acrylamide, acrylic acid ester, styrene, vinylimidazole, vinylpyridine, sodium p-styrenesulfonate and the like are graft-copolymerized on the hydroxyl. According to the lithium-ion battery of the present disclosure, a stable SEI interface can be formed on a surface of a silicon-based negative electrode, so that the lithium-ion battery prepared thereby has high energy density, long cycle life and low cycle expansion rate.

Abstract: The present application provides a boric acid derivative modified binder and a lithium-ion battery including the binder. Surfaces of emulsion particles of the binder are rich in boric acid groups (—B(OH)2). When the binder is applied to an electrode piece of the battery, the boric acid groups can be subjected to a dehydration condensation reaction with —OH in sodium carboxymethyl cellulose dispersant, or with —OH in a functional monomer during the drying process of the electrode piece, to form a three-dimensional network, increasing the bonding force and greatly improving the peeling strength of the electrode piece. The binder can also significantly improve the cycle performance of the lithium-ion battery, thereby prolonging the cycle life of the lithium-ion battery.

Abstract: The present application provides a binder and a lithium-ion battery including the binder. The binder is rich in amino groups, has strong alkali resistance and is not easy to decompose. Besides, rich amino groups in the binder are prone to form hydrogen bonds, so that the binder more fully coats an active material and can enhance an acting force between the active material and a current collector, improve a peeling strength of an electrode piece, and significantly improve a cycling performance, expansion rate, and rate capability of lithium-ion batteries using the binder.

Abstract: Disclosed are a binder and a battery including the binder. The novel aqueous binder with self cross-linking performance, strong bonding performance, and good flexibility is obtained by copolymerizing a plurality of functional monomers. The binder has the characteristics of good processability and high solid content of the slurry when applied to a positive electrode; the positive electrode plate obtained by applying the slurry has high peeling force and good cyclic stability, and its rate capability is superior to that obtained by applying PVDF binder; and the binder is green and environmental friendly, and it is expected to replace PVDF in batteries and achieve large-scale application.

Abstract: Disclosed are a pre-lithiated silicon negative electrode material, a silicon negative electrode plate, a method for preparing the same, and a lithium-ion battery. The pre-lithiated silicon negative electrode material includes a silicon negative electrode material and a lithium-containing polymer compounded with the silicon negative electrode material. The lithium-containing polymer includes a polymer shown in the following formula 1, where x is 1 to 12, and R1 is I; or II, where y is 1 to 4; or III or IV. The use of the pre-lithiated silicon negative electrode material can improve performance, such as initial Coulombic efficiency, of a lithium-ion battery.

Abstract: Disclosed are a negative electrode plate and a battery. A first negative active material layer is disposed at a bottom layer, and includes a first binder resistant to electrolyte swelling, has a better chemical corrosion resistance, and is not easy to age, so as to ensure long-term bonding, and reduce battery cell expansio. The negative electrode plate can maintain good mechanical strength and elongation at immersion of the electrolyte, so as to ensure that it is not separatedr. A second binder in a second negative active material layer away from the negative current collector uses a high swelling material, the high-swelling binder is in good affinity with the electrolyte, and the electrolyte infiltration speed is good, which facilitates lithium ion conduction. Furthermore, the high-swelling binder is bound to the separator well in a hot pressing process, so as to improve an interface bonding effect.

Abstract: The present invention relates to pegylated amino acid compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3A, R3B and n are as defined herein. The present invention also relates to compositions which comprise a pegylated amino acid compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, in combination with a high concentration of an active biological ingredient (ABI). In embodiments of the invention, the ABI is an anti-PD-1 antibody or antigen binding fragment thereof that specifically binds human programmed death receptor 1 (PD-1). The invention further relates to methods for lowering the viscosity of an aqueous solution of a pharmaceutical composition comprising adding a compound of the invention to the solution.

Abstract: The present invention relates to pegylated amino acid compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3A, R3B and n are as defined herein. The present invention also relates to compositions which comprise a pegylated amino acid compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, in combination with a high concentration of an active biological ingredient (ABI). In embodiments of the invention, the ABI is an anti-PD-1 antibody or antigen binding fragment thereof that specifically binds human programmed death receptor 1 (PD-1). The invention further relates to methods for lowering the viscosity of an aqueous solution of a pharmaceutical composition comprising adding a compound of the invention to the solution.

Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis.

Abstract: Cyclohexyl sulfonamide compounds which are platelet-activating factor (PAF) receptor antagonists. Said compounds may be useful, for example, for the treatment of atherosclerosis or other PAF-mediated disorders, including inflammatory, cardiovascular, and immune disorders.

Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis.

Abstract: Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

Abstract: The instant invention provides compounds of formula I which are 5-lipoxygenase activating protein inhibitors. Compounds of formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

Abstract: This invention provides compounds of Formula I which are PAFR antagonists: I and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preventing or reducing risk for atherosclerotic disease events. The compounds are also useful for treating or ameliorating pain, e.g. inflammatory pain and/or nociceptive pain, and for treating or ameliorating autoimmune and/or inflammatory diseases, among other conditions.

Abstract: Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

Abstract: The instant invention provides compounds of Formula I which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

Abstract: The instant invention provides compounds of Formula II which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula II are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.